Jennifer Grancio Net Worth

The estimated Net Worth of Jennifer Grancio is at least $1.5 Million dollars as of 28 February 2022. Ms. Grancio owns over 110,701 units of Mannkind Corp stock worth over $1,500,716 and over the last 5 years she sold MNKD stock worth over $0. In addition, she makes $0 as Independent Director at Mannkind Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Grancio MNKD stock SEC Form 4 insiders trading

Jennifer has made over 1 trades of the Mannkind Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently she bought 110,701 units of MNKD stock worth $300,000 on 28 February 2022.

The largest trade she's ever made was buying 110,701 units of Mannkind Corp stock on 28 February 2022 worth over $300,000. On average, Jennifer trades about 15,814 units every 0 days since 2020. As of 28 February 2022 she still owns at least 244,815 units of Mannkind Corp stock.

You can see the complete history of Ms. Grancio stock trades at the bottom of the page.

Jennifer Grancio biography

Jennifer Grancio serves as Independent Director of the Company. Ms. Grancio served as a founder and executive with BlackRock's iShares business from 1999 to 2018. She spearheaded the distribution of iShares in the United States and Europe and acted as the Global Head of Marketing and Partnerships for BlackRock's indexing service. Through those efforts, Ms. Grancio established herself as a global leader in exchange-traded and mutual funds. Since her time at BlackRock, she founded Grancio Capital, where she consults with company leaders on the best ways to expand market reach and how to build effective teams to do so. Previously, she was a senior associate with PricewaterhouseCoopers, a management consulting firm. She earned a bachelor's degree in economics and international relations from Stanford University, and an MBA degree in strategy and finance from Columbia Business School.

How old is Jennifer Grancio?

Jennifer Grancio is 48, she's been the Independent Director of Mannkind Corp since 2020. There are 19 older and 3 younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.

What's Jennifer Grancio's mailing address?

Jennifer's mailing address filed with the SEC is 1, Casper Street, Danbury, Fairfield County, Connecticut, 06810, United States.

Insiders trading at Mannkind Corp

Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens und David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.

What does Mannkind Corp do?

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.

Complete history of Ms. Grancio stock trades at Mannkind Corp

Mannkind Corp executives and stock owners

Mannkind Corp executives and other stock owners filed with the SEC include:

• Michael Castagna,
  Chief Executive Officer, Director
• Dr. Michael E. Castagna Pharm.D.,
  CEO & Director
• Stuart Tross,
  Chief People and Workplace Officer
• David Thomson,
  Executive Vice President, General Counsel, Secretary
• Dr. Michael E. Castagna,
  CEO & Director
• Steven Binder,
  Chief Financial Officer
• Dr. David B. Thomson,
  Exec. VP, Gen. Counsel & Sec.
• Joseph Kocinsky,
  Chief Technology Officer
• Steven B. Binder,
  Chief Financial Officer
• Joseph Kocinsky M.B.A., M.S.,
  Chief Technology Officer
• Dr. Stuart A. Tross,
  Chief People & Workplace Officer
• Rosabel Alinaya,
  Vice President of Investor Relations, Interim Corporate Controller, Treasurer
• Christine Mundkur,
  Independent Director
• Kent Kresa,
  Independent Chairman of the Board
• Ronald Consiglio,
  Independent Director
• Michael Friedman,
  Independent Director
• James Shannon,
  Independent Director
• Kevin Kaiserman,
  Vice President - Medical Affairs and Safety
• Jennifer Grancio,
  Independent Director
• Anthony Hooper,
  Independent Director
• Alejandro Galindo M.B.A., M.S.,
  Chief Commercial Officer
• James Patrick McCauley Jr., J.D., M.B.A.,
  Chief Commercial Officer
• John F. Bedard,
  Sr. VP of Worldwide Regulatory Affairs
• Rosabel Realica Alinaya,
  VP of Investor Relations & Treasury
• Thomas Hofmann M.D., Ph.D.,
  Chief Scientific Officer
• Matthew J Pfeffer,
  Corporate VP and CFO
• Henry L Nordhoff,
  Director
• David Mac Callum,
  Director
• Raymond W. Urbanski,
  Corp VP, CMO
• David M Kendall,
  Chief Medical Officer
• Elizabeth Garrett Ingram,
  Chief Marketing Officer
• Courtney Barton,
  Chief Compl & Privacy Officer
• Patrick Mc Cauley,
  Chief Commercial Officer
• John R. Riesenberger,
  VP & Chief Commercial Officer
• Richard L Anderson,
  VP & CFO
• Heather Hay Murren,
  Director
• Kathleen Connell,
  Director
• Llew Keltner,
  Director
• Dan Burns,
  VP & President, MKBP
• W Wendell Cheatham,
  VP, Medical & Reg Affairs
• Juergen Martens,
  Corporate VP
• Hakan Edstrom,
  President & COO
• Alfred E Mann,
  Chairman & CEO
• Diane Palumbo,
  Vice President, Human Resource
• Abraham E Cohen,
  Director
• Peter C Richardson,
  Chief Scientific Officer
• Lauren M Sabella,
  EVP Chief Operating Officer
• Alejandro Galindo,
  EVP Endocrine Business Unit
• Burkhard Blank,
  EVP Chief Medical Officer
• Sanjay R Singh,
  EVP Technical Operations
• Christopher B Prentiss,
  Chief Financial Officer
• Sabrina Kay,